Partner login Start About us Products News Partners Contact Finance Meet Us MonoTotal For high sensitivity in NSCLC ‹ › Patent approved in China During 2015 the patent ”Method for detection of cytokeratin 8, 18 and/or 19 and/or soluble fragments thereof” was approved in Sweden. The patent has now been approved in China and is valid until 2034. Read more here Positive results for UBC® Rapid in an Austrian study Read the news here IDL will participate at MEDICA, the world’s largest event for the medical sector. Medica is held 13-16 November, 2017, in Düssseldorf, Germany. You will find us in Hall 3A, booth D28. IDL will also participate in the Swedish Association of Urology in Gothenburg, Sweden October 4-6, 2017. Positive results for UBC® Rapid - UBC® Rapid is recommended to be added in the diagnostics of high grade bladder cancer tumours in a German multicenter study. Read more here - Positive results for UBC® Rapid in a Swedish multicenter study. Read more here Oncology products Cytokeratin Tumor markers > TPS® > MonoTotal® > TPAcykTM > UBC® Bacteriology products Detection of acute typhoid fever > TUBEX® TF Products TPS® MonoTotal® UBC® TPAcyk® TUBEX® TF The Company About us Management News Contact us Partners Legal disclaimer Contact us IDL Biotech AB (publ) PO Box 11151 SE-161 11 Bromma Sweden Phone: +46 8 799 67 50 E-mail: idlbiotech@idl.se